Found: 25
Select item for more details and to access through your institution.
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 927, doi. 10.1007/s10637-018-0631-8
- By:
- Publication type:
- Article
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 919, doi. 10.1007/s10637-018-0630-9
- By:
- Publication type:
- Article
Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 952, doi. 10.1007/s10637-018-0608-7
- By:
- Publication type:
- Article
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 903, doi. 10.1007/s10637-018-0617-6
- By:
- Publication type:
- Article
Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 895, doi. 10.1007/s10637-018-0615-8
- By:
- Publication type:
- Article
GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 955, doi. 10.1007/s10637-018-0613-x
- By:
- Publication type:
- Article
Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 911, doi. 10.1007/s10637-018-0621-x
- By:
- Publication type:
- Article
Crizotinib-induced simultaneous multiple cardiac toxicities.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 949, doi. 10.1007/s10637-018-0605-x
- By:
- Publication type:
- Article
The in vitro assessment of dipyridophenazine complexes in H-ras oncogene transformed rat embryo fibroblast 5RP7 cell line.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 755, doi. 10.1007/s10637-017-0559-4
- By:
- Publication type:
- Article
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 886, doi. 10.1007/s10637-018-0588-7
- By:
- Publication type:
- Article
Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 797, doi. 10.1007/s10637-018-0569-x
- By:
- Publication type:
- Article
The concomitant use of lapatinib and paracetamol - the risk of interaction.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 819, doi. 10.1007/s10637-018-0573-1
- By:
- Publication type:
- Article
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 939, doi. 10.1007/s10637-018-0589-6
- By:
- Publication type:
- Article
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 848, doi. 10.1007/s10637-018-0562-4
- By:
- Publication type:
- Article
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 877, doi. 10.1007/s10637-018-0582-0
- By:
- Publication type:
- Article
Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 782, doi. 10.1007/s10637-018-0568-y
- By:
- Publication type:
- Article
First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 860, doi. 10.1007/s10637-018-0567-z
- By:
- Publication type:
- Article
Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 810, doi. 10.1007/s10637-018-0571-3
- By:
- Publication type:
- Article
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 869, doi. 10.1007/s10637-018-0570-4
- By:
- Publication type:
- Article
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 763, doi. 10.1007/s10637-018-0563-3
- By:
- Publication type:
- Article
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 836, doi. 10.1007/s10637-018-0560-6
- By:
- Publication type:
- Article
SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 773, doi. 10.1007/s10637-018-0566-0
- By:
- Publication type:
- Article
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 828, doi. 10.1007/s10637-017-0551-z
- By:
- Publication type:
- Article
Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 933, doi. 10.1007/s10637-017-0549-6
- By:
- Publication type:
- Article
Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 743, doi. 10.1007/s10637-017-0558-5
- By:
- Publication type:
- Article